TRAW · Traws Pharma, Inc.
$0.57
+0.02 (+4.25%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current projections, the Company believes that it does not have sufficient cash and cash equivalents to support its operations for more than one year following the date that these financial statements are issued. As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$8.66M
Shares
15.37M
Volume · Oct 2
69.63K
Avg daily vol (3M)
570.37K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.57
Open$0.56
Day$0.55–0.57
52W close$0.44–3.13
Avg vol 30d1.1M
Short int612K · 4.0% float · 8.6d
Short vol28%
Last earningsApr 15, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
call held Aug 14, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-68.8%
Trailing year
Short interest
4.0%
Latest settlement · 8.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−55%
below
Price vs 50-day avg
+5%
above
RSI (14)
52
neutral
MACD trend
Positive
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
−65%
trailing
YTD return
−50%
this year
Relative strength
−77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.98% of float · ▼ -3.3% MoM · 8.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+1135%
Y/Y
EPS growth
+102%
Y/Y
Free cash flow
$-18.2M
Quant / Vol
risk profile
Volatility
131%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
9.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−55%
Bearish
Price vs 50-day avg
+5%
Bullish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +14 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.98% of float · ▼ -3.3% MoM · 8.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $1 · 5%
Range high $3
vs 200-day avg -55%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRAW
this stock
Traws Pharma, Inc.
|
$8.66M | -49.7% | +1134.5% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRAW | +0.9% | +4.9% | -64.7% | -4.3% | -49.7% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +1.2% | +5.4% | -76.9% | -5.2% | -62.6% |